Terran Biosciences (“Terran”), a biotechnology platform company focused on the development of transformational drugs for neurological and psychiatric diseases, has entered into an agreement with Concert Pharmaceuticals (“Concert”) to acquire Concert’s portfolio of CNS therapeutics, including related intellectual property.
Terran Biosciences announces the acquisition of a new CNS drug portfolio from Concert Pharmaceuticals
